In HF with LVEF ≤ 42.5%, sacubitril-valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization.
Sen S, Newby LK. In HF with LVEF ≤ 42.5%, sacubitril-valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization. Annals Of Internal Medicine 2020, 172: jc65. PMID: 32539517, DOI: 10.7326/acpj202006160-065.Peer-Reviewed Original ResearchConceptsSacubitril/valsartan